InfuSystem Holdings, Inc.

What they do

The company provides turnkey clinic-to-home healthcare solutions, including Durable Medical Equipment (DME) and treatment consumables, order and delivery logistics, 24/7 nursing support, third-party payer billing, and biomedical services. Its two-platform model consists of Patient Services (last-mile solutions for complex DME) and Device Solutions (a 'concierge' offering with equipment rental and sales, consumable sales, and biomedical support). It operates from seven locations in the U.S. and Canada, serving hospitals, oncology practices, ambulatory surgery centers, and other alternate site providers.

Revenue drivers

• Patient Services — Largest segment, generating $24.8 million in Q2 2026 (67% of total revenue), up 15% year-over-year. Growth driven by oncology and wound care treatment volume and improved payer collections.
• Oncology — Within Patient Services, surpassed $20 million in quarterly revenue for the first time in Q2 2026, benefiting from additional volume and collections.
• Wound Care (including compression therapy) — Rapid growth segment, revenue up 154% in Q2 2026, driven by adoption of new lymphedema compression therapy offerings (Pneumatic Compression Devices and Adjustable Compression Wraps) from two new supplier relationships.
• Device Solutions — Generates $12.1 million in Q2 2026 (33% of total revenue), down 16% year-over-year due to restructuring of the largest biomedical services contract (GE Healthcare).

Recent performance

In Q2 2026, net revenues totaled $36.9 million, up 2.6% from $36.0 million in the prior-year period. Patient Services revenue increased 15.2% to $24.8 million, while Device Solutions declined 16% to $12.1 million. Gross profit rose 8% to $21.4 million (58% gross margin), and net income was $3.2 million or $0.15 per diluted share, compared to $2.6 million or $0.12 per share in Q2 2025. Adjusted EBITDA (non-GAAP) was $8.6 million with a 23.4% margin, up 1.1% year-over-year. Company had $55.2 million in liquidity as of June 30, 2026.

Strategy

Management is focused on driving sustainable growth by leveraging its existing infrastructure (sales, clinical, logistics, revenue cycle management, biomedical services) to extend its oncology Patient Services model into other DME therapies. The company is investing in information technology, including a new enterprise resource planning (ERP) platform, to improve scalability and efficiency. It is expanding into high-growth areas like compression therapy for wound care and optimizing payer networks and manufacturer partnerships. The restructuring of the GE Healthcare contract was a strategic move that reduced revenue but improved profitability through greater direct cost reductions.

Risks

• Reimbursement dependency — Substantial dependence on third-party reimbursement from private insurers and governmental agencies, with any reduction in allowable fees materially impacting revenues.
• Healthcare reform and payer mix changes — Changes in the healthcare reimbursement system, including ACO growth, competitive bidding, and fee schedule reductions, could discourage use of its therapies and reduce profitability.
• Customer concentration and contract restructuring — Loss or restructuring of key contracts, as seen with GE Healthcare, can significantly reduce revenue, though it may improve margins.
• Operational and external disruptions — Public health emergencies, extreme weather, cybersecurity incidents, labor/supply chain disruptions, and inflation could adversely affect operations and financial results.

Outlook

Management reaffirmed full-year 2026 guidance, expecting 6% to 8% pro forma revenue growth, excluding the impact of the GE Healthcare restructuring (which reduced revenue by $7.1 million for the full year). The company remains focused on disciplined execution, maintaining strong EBITDA margins, and creating long-term shareholder value. It expects to continue expanding its compression therapy business and leveraging its payer network and operational capabilities for growth.